Overall, the combination of co-stimulatory molecules targeting CD28 is influenced by tumor type, tumor microenvironment, and CAR structure, and the optimal mode of co-stimulatory molecule tandem will need to be determined in the future based on specific tumors. The gene discussed is CD28; the disease is neoplasm.